Bio-Techne Stock (TECH)

XNGS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Bio-Techne is a US provider of products for research and diagnostics. The company supplies proteins, antibodies and reagents for labs as well as analytical instruments and diagnostic tests. Customers are universities, pharmaceutical companies and hospitals worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Biotechnology and vaccines · Minneapolis, USA

The company develops, manufactures and sells reagents, instruments and services for research, diagnostics and bioprocessing worldwide. The Protein Sciences segment supplies biological reagents such as cytokines, antibodies and small molecules as well as protein analysis instruments, for example under the R&D Systems, Tocris Biosciences and ProteinSimple brands. Customers of this segment include researchers in academia and industry, there mainly in pharmaceutical and biotech companies; sales run directly, through a distribution agreement with Thermo Fisher Scientific and through other distributors. The Diagnostics and Spatial Biology segment offers in situ hybridization (ISH) assays under the ACD brand as well as diagnostic products under the Asuragen brand. Diagnostic controls and calibrators go mainly to instrument makers as OEM supplies.

Automatically summarized from SEC annual report (10-K, filed Aug 24, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −0.0%
  • 7 days −0.1%
  • 30 days +0.1%
  • 1 year +23.8%
Day range (last trading day)
0.0%Price at 33% of the range+0.1%
52-week range
−40.6%Price at 99% of the range+0.3%
Distance from the all-time high
−46.5%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Bio-Techne · Sector Health Care · amounts in USD

Source: SEC filings, As of Aug 24, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 5.2x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
0.0%
dividend per share, average per year
Coverage by free cash flow
5.2x
covered from 1.0x

For you first Valuation

The P/E is about at its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
4 of 7
criteria with data met
Revenue per year (5 y)
+5.5%
EPS per year (5 y)
+6.0%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
7 of 8
criteria with data met
Net margin
15.0%
Cash flow ÷ profit
1.61x
backed from 1.0 · 3 years: 2.08x

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Jun 30, 2026

Quality 7 of 8 met

  • met: Gross margin above 40% 65.8%
  • met: Operating margin above 15% 20.7%
  • met: Net margin above 10% 15.0%
  • not met: Return on equity above 15% 8.6%
  • met: Free cash flow margin above 10% 21.7%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 81.5%
Gross margin

65.8% Fiscal year 2026

Rank 76 of 100: higher than 76% of 370 peers (All). strong.

Rank 58 of 100: higher than 58% of 49 peers (Sector). medium.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

20.7% Fiscal year 2026

Rank 66 of 100: higher than 66% of 470 peers (All). medium.

Rank 71 of 100: higher than 71% of 54 peers (Sector). strong.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

15.0% Fiscal year 2026

Rank 62 of 100: higher than 62% of 584 peers (All). medium.

Rank 63 of 100: higher than 63% of 63 peers (Sector). medium.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

8.6% Fiscal year 2026

Rank 32 of 100: higher than 32% of 544 peers (All). weak.

Rank 27 of 100: higher than 27% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

7.0% Fiscal year 2026 (total assets at year end)

Rank 63 of 100: higher than 63% of 594 peers (All). medium.

Rank 55 of 100: higher than 55% of 63 peers (Sector). medium.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

81.5% Fiscal year 2026

Rank 96 of 100: higher than 96% of 595 peers (All). strong.

Rank 98 of 100: higher than 98% of 63 peers (Sector). strong.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

21.7% Fiscal year 2026

Rank 80 of 100: higher than 80% of 465 peers (All). strong.

Rank 78 of 100: higher than 78% of 61 peers (Sector). strong.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

263.2M USD Fiscal year 2026

Operating cash flow minus capital expenditure on property and equipment.

Growth 4 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year +2.2%
  • met: Over 5 years, revenue grew by more than 5% per year +5.5%
  • met: Over 10 years, revenue grew by more than 5% per year +9.3%
  • not met: Over 3 years, EPS grew by more than 5% per year −13.0%
  • met: Over 5 years, EPS grew by more than 5% per year +6.0%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • not met: Revenue rose in the last fiscal year −0.4%
Revenue growth 3 years

+2.2% per year

Rank 31 of 100: higher than 31% of 578 peers (All). weak.

Rank 36 of 100: higher than 36% of 62 peers (Sector). medium.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+5.5% per year

Rank 30 of 100: higher than 30% of 549 peers (All). weak.

Rank 29 of 100: higher than 29% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+9.3% per year

Rank 67 of 100: higher than 67% of 412 peers (All). strong.

Rank 51 of 100: higher than 51% of 50 peers (Sector). medium.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

−13.0% per year

Rank 16 of 100: higher than 16% of 437 peers (All). weak.

Rank 16 of 100: higher than 16% of 54 peers (Sector). weak.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+6.0% per year

Rank 31 of 100: higher than 31% of 399 peers (All). weak.

Rank 37 of 100: higher than 37% of 47 peers (Sector). medium.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+5.2% per year

Rank 28 of 100: higher than 28% of 375 peers (All). weak.

Rank 27 of 100: higher than 27% of 46 peers (Sector). weak.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 7 met

  • met: Pays a dividend 0.32 USD
  • met: Payout ratio at most 60% of earnings 28%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • not met: Dividend per share higher than 5 years ago 0.0%
  • met: Free cash flow per share covers the dividend 5.2x
  • met: Dividends paid over the last 5 years covered by free cash flow 20% of free cash flow
Payout ratio

28% Fiscal year 2026

Dividend per share divided by earnings per share.

Dividend growth 5 years

0.0% per year

Rank 6 of 100: higher than 6% of 321 peers (All). weak.

Rank 8 of 100: higher than 8% of 31 peers (Sector). weak.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

5.2x Fiscal year 2026

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 6 of 6 met

  • met: Piotroski F-Score at least 7 of 9 9 of 9
  • met: Long-term debt no higher than equity 0.09
  • met: Current assets cover current liabilities 4.55
  • met: Positive equity 2.1B USD
  • met: In 5 years, share count up by at most 5% −3.0%
  • met: Free cash flow positive in the last fiscal year 263.2M USD
Piotroski F-Score

9 of 9 Fiscal year 2026

Rank 98 of 100: higher than 98% of 310 peers (All). strong.

Rank 96 of 100: higher than 96% of 47 peers (Sector). strong.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.09 at fiscal year end

Rank 90 of 100: lower than 90% of 486 peers (All). strong.

Rank 87 of 100: lower than 87% of 50 peers (Sector). strong.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

4.55 at fiscal year end

Rank 93 of 100: higher than 93% of 513 peers (All). strong.

Rank 94 of 100: higher than 94% of 63 peers (Sector). strong.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−3.0% in 5 years

Rank 51 of 100: lower than 51% of 507 peers (All). medium.

Rank 43 of 100: lower than 43% of 59 peers (Sector). medium.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+5.5% per year), more slowly than the sector median.
  • Light yellow: Net income (total) grew over 5 years (+5.3% per year), more slowly than the sector median; per share +6.0% per year.
  • Light green: Net margin 15.0%, above the sector median (13.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2017 (Jul 1, 2016 – Jun 30, 2017): Revenue 563.0M USD · Net income 76.1M USD · Net margin 13.5%
  2. Fiscal year 2018 (Jul 1, 2017 – Jun 30, 2018): Revenue 643.0M USD · Net income 126.2M USD · Net margin 19.6%
  3. Fiscal year 2019 (Jul 1, 2018 – Jun 30, 2019): Revenue 714.0M USD · Net income 96.1M USD · Net margin 13.5%
  4. Fiscal year 2020 (Jul 1, 2019 – Jun 30, 2020): Revenue 738.7M USD · Net income 229.3M USD · Net margin 31.0%
  5. Fiscal year 2021 (Jul 1, 2020 – Jun 30, 2021): Revenue 931.0M USD · Net income 140.4M USD · Net margin 15.1%
  6. Fiscal year 2022 (Jul 1, 2021 – Jun 30, 2022): Revenue 1.1B USD · Net income 272.1M USD · Net margin 24.6%
  7. Fiscal year 2023 (Jul 1, 2022 – Jun 30, 2023): Revenue 1.1B USD · Net income 285.3M USD · Net margin 25.1%
  8. Fiscal year 2024 (Jul 1, 2023 – Jun 30, 2024): Revenue 1.2B USD · Net income 168.1M USD · Net margin 14.5%
  9. Fiscal year 2025 (Jul 1, 2024 – Jun 30, 2025): Revenue 1.2B USD · Net income 73.4M USD · Net margin 6.0%
  10. Fiscal year 2026 (Jul 1, 2025 – Jun 30, 2026): Revenue 1.2B USD · Net income 181.9M USD · Net margin 15.0%

Fiscal year 2026 (Jul 1, 2025 – Jun 30, 2026): Revenue 1.2B USD · Net income 181.9M USD · Net margin 15.0%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +4.6% vs. the same quarter a year earlier; grown for 2 quarters in a row.

Revenue 12 months vs. prior 12
+0.9%
12 months: 1.2B USD · Fiscal year 2026: −0.4%
Net margin 12 months
14.0%
Fiscal year 2026: 15.0%
Free cash flow margin 12 months
25.1%
Fiscal year 2026: 21.7%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Jun 30, 2026 1.2B USD + year to date to Sep 30, 2026 299.7M USD − same period a year earlier to Sep 30, 2025 286.6M USD = 1.2B USD
  • Net income: fiscal year to Jun 30, 2026 181.9M USD + year to date to Sep 30, 2026 28.3M USD − same period a year earlier to Sep 30, 2025 38.2M USD = 172.0M USD
  • Operating cash flow: fiscal year to Jun 30, 2026 292.1M USD + year to date to Sep 30, 2026 73.1M USD − same period a year earlier to Sep 30, 2025 27.6M USD = 337.6M USD
  • Capital expenditure: fiscal year to Jun 30, 2026 28.9M USD + year to date to Sep 30, 2026 5.9M USD − same period a year earlier to Sep 30, 2025 5.4M USD = 29.4M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 26299.7M+4.6%28.3M9.4%
Apr–Jun 26*321.2M+1.3%––
Jan–Mar 26311.4M−1.5%51.0M16.4%
Oct–Dec 25295.9M−0.4%38.0M12.8%
Jul–Sep 25286.6M−1.0%38.2M13.3%
Apr–Jun 25*317.0M–−17.7M−5.6%
Jan–Mar 25316.2M–22.6M7.1%
Oct–Dec 24297.0M–34.9M11.7%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 6, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is well covered.

Cash flow ÷ profit
1.61x
backed from 1.0 · 3 years: 2.08x
Interest coverage
26.2x
well covered from 5 · 3 years: 16.6x
Tax rate
24.4%
for information only · 3 years: 19.3%
More depth

Calculation for fiscal year 2026

  • Operating cash flow 292.1M USD ÷ Net income 181.9M USD = 1.61x
  • Operating income 251.9M USD ÷ Interest expense 9.6M USD = 26.2x
  • Taxes 58.8M USD ÷ profit before tax 240.7M USD = 24.4%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20261.61x26.2x24.4%
20253.92x12.0x25.5%
20241.78x13.1x9.5%
20230.89x26.7x15.7%
20221.24x26.2x12.7%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2026 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year and one year with lower revenue.

Loss years
0 of 10
net income below zero
Years with lower revenue
1 of 10
revenue below the prior year
Net margin range
25.0 percentage points
from 6.0% to 31.0%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2026−0.4%15.0%
2025+5.2%6.0%
2024+2.0%14.5%
2023+2.8%25.1%
2022+18.7%24.6%
2021+26.0%15.1%
2020+3.5%31.0%
2019+11.0%13.5%
2018+14.2%19.6%
2017+12.8%13.5%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2017–2026 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2026

Of 100 USD of revenue, 65.8 USD gross profit, 20.7 USD operating income and 15.0 USD net income remained.

Money flow as a table
Fiscal year 2026, amounts in USD, share of revenue
ItemAmountof revenue
Revenue1.2B USD100.0%
Gross profit799.1M USD65.8%
Cost of revenue416.0M USD34.2%
Operating income251.9M USD20.7%
Research & development94.8M USD7.8%
Other operating expenses452.4M USD37.2%
Net income181.9M USD15.0%
Interest expense9.6M USD0.8%
Taxes58.8M USD4.8%
Other1.6M USD0.1%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 25.5% to 20.7%.

Gross marginOperating marginNet margin
  1. Fiscal year 2017: Gross margin 66.5% · Operating margin 21.4% · Net margin 13.5%
  2. Fiscal year 2018: Gross margin 67.2% · Operating margin 21.2% · Net margin 19.6%
  3. Fiscal year 2019: Gross margin 66.3% · Operating margin 20.5% · Net margin 13.5%
  4. Fiscal year 2020: Gross margin 65.4% · Operating margin 21.3% · Net margin 31.0%
  5. Fiscal year 2021: Gross margin 68.0% · Operating margin 25.5% · Net margin 15.1%
  6. Fiscal year 2022: Gross margin 68.4% · Operating margin 26.8% · Net margin 24.6%
  7. Fiscal year 2023: Gross margin 67.7% · Operating margin 26.3% · Net margin 25.1%
  8. Fiscal year 2024: Gross margin 66.4% · Operating margin 17.8% · Net margin 14.5%
  9. Fiscal year 2025: Gross margin 64.8% · Operating margin 8.4% · Net margin 6.0%
  10. Fiscal year 2026: Gross margin 65.8% · Operating margin 20.7% · Net margin 15.0%

Returns

Return on equity stayed roughly the same in 5 years (8.6%).

Return on equityReturn on assets
  1. Fiscal year 2017: Return on equity 8.0% · Return on assets 4.9%
  2. Fiscal year 2018: Return on equity 11.7% · Return on assets 7.9%
  3. Fiscal year 2019: Return on equity 8.2% · Return on assets 5.1%
  4. Fiscal year 2020: Return on equity 16.6% · Return on assets 11.3%
  5. Fiscal year 2021: Return on equity 9.0% · Return on assets 6.2%
  6. Fiscal year 2022: Return on equity 16.0% · Return on assets 11.9%
  7. Fiscal year 2023: Return on equity 14.5% · Return on assets 10.8%
  8. Fiscal year 2024: Return on equity 8.1% · Return on assets 6.2%
  9. Fiscal year 2025: Return on equity 3.8% · Return on assets 2.9%
  10. Fiscal year 2026: Return on equity 8.6% · Return on assets 7.0%

Equity and long-term debt

The equity ratio rose in 5 years from 69.1% to 81.5%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2017: Equity 949.6M USD · Long-term debt 343.8M USD
  2. Fiscal year 2018: Equity 1.1B USD · Long-term debt 339.0M USD
  3. Fiscal year 2019: Equity 1.2B USD · Long-term debt 492.7M USD
  4. Fiscal year 2020: Equity 1.4B USD · Long-term debt 344.2M USD
  5. Fiscal year 2021: Equity 1.6B USD · Long-term debt 328.8M USD
  6. Fiscal year 2022: Equity 1.7B USD · Long-term debt 243.4M USD
  7. Fiscal year 2023: Equity 2.0B USD · Long-term debt 350.0M USD
  8. Fiscal year 2024: Equity 2.1B USD · Long-term debt 319.0M USD
  9. Fiscal year 2025: Equity 1.9B USD · Long-term debt 346.0M USD
  10. Fiscal year 2026: Equity 2.1B USD · Long-term debt 200.0M USD

Liquidity (current ratio)

The current ratio rose in 5 years from 3.35 to 4.55.

Current ratio
  1. Fiscal year 2017: Current ratio 2.57
  2. Fiscal year 2018: Current ratio 5.01
  3. Fiscal year 2019: Current ratio 4.05
  4. Fiscal year 2020: Current ratio 4.88
  5. Fiscal year 2021: Current ratio 3.35
  6. Fiscal year 2022: Current ratio 3.44
  7. Fiscal year 2023: Current ratio 4.84
  8. Fiscal year 2024: Current ratio 3.87
  9. Fiscal year 2025: Current ratio 3.46
  10. Fiscal year 2026: Current ratio 4.55

Cash flow

Free cash flow fell in 5 years from 307.9M USD to 263.2M USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2017: Operating cash flow 143.7M USD · Capital expenditure 15.2M USD · Free cash flow 128.5M USD
  2. Fiscal year 2018: Operating cash flow 170.4M USD · Capital expenditure 20.9M USD · Free cash flow 149.4M USD
  3. Fiscal year 2019: Operating cash flow 181.6M USD · Capital expenditure 25.4M USD · Free cash flow 156.2M USD
  4. Fiscal year 2020: Operating cash flow 205.2M USD · Capital expenditure 51.7M USD · Free cash flow 153.5M USD
  5. Fiscal year 2021: Operating cash flow 352.2M USD · Capital expenditure 44.3M USD · Free cash flow 307.9M USD
  6. Fiscal year 2022: Operating cash flow 325.3M USD · Capital expenditure 44.9M USD · Free cash flow 280.4M USD
  7. Fiscal year 2023: Operating cash flow 254.4M USD · Capital expenditure 38.2M USD · Free cash flow 216.1M USD
  8. Fiscal year 2024: Operating cash flow 299.0M USD · Capital expenditure 62.9M USD · Free cash flow 236.1M USD
  9. Fiscal year 2025: Operating cash flow 287.6M USD · Capital expenditure 31.0M USD · Free cash flow 256.6M USD
  10. Fiscal year 2026: Operating cash flow 292.1M USD · Capital expenditure 28.9M USD · Free cash flow 263.2M USD

Share count

The share count fell in 5 years by 3.0% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2017: Diluted share count 150.0M
  2. Fiscal year 2018: Diluted share count 152.2M
  3. Fiscal year 2019: Diluted share count 155.6M
  4. Fiscal year 2020: Diluted share count 157.6M
  5. Fiscal year 2021: Diluted share count 161.9M
  6. Fiscal year 2022: Diluted share count 164.1M
  7. Fiscal year 2023: Diluted share count 161.9M
  8. Fiscal year 2024: Diluted share count 160.8M
  9. Fiscal year 2025: Diluted share count 159.7M
  10. Fiscal year 2026: Diluted share count 157.0M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Revenue

Revenue rose in 5 years from 931.0M USD to 1.2B USD.

TECH in USD
  1. Fiscal year 2017: TECH 563.0M USD
  2. Fiscal year 2018: TECH 643.0M USD
  3. Fiscal year 2019: TECH 714.0M USD
  4. Fiscal year 2020: TECH 738.7M USD
  5. Fiscal year 2021: TECH 931.0M USD
  6. Fiscal year 2022: TECH 1.1B USD
  7. Fiscal year 2023: TECH 1.1B USD
  8. Fiscal year 2024: TECH 1.2B USD
  9. Fiscal year 2025: TECH 1.2B USD
  10. Fiscal year 2026: TECH 1.2B USD

Net margin

The net margin stayed roughly the same in 5 years (15.0%).

TECH Sector today 14.6% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2017: TECH 13.5%
  2. Fiscal year 2018: TECH 19.6%
  3. Fiscal year 2019: TECH 13.5%
  4. Fiscal year 2020: TECH 31.0%
  5. Fiscal year 2021: TECH 15.1%
  6. Fiscal year 2022: TECH 24.6%
  7. Fiscal year 2023: TECH 25.1%
  8. Fiscal year 2024: TECH 14.5%
  9. Fiscal year 2025: TECH 6.0%
  10. Fiscal year 2026: TECH 15.0% · Sector today 14.6%

Free cash flow margin

The free cash flow margin fell in 5 years from 33.1% to 21.7%.

TECH Sector today 15.8%
  1. Fiscal year 2017: TECH 22.8%
  2. Fiscal year 2018: TECH 23.2%
  3. Fiscal year 2019: TECH 21.9%
  4. Fiscal year 2020: TECH 20.8%
  5. Fiscal year 2021: TECH 33.1%
  6. Fiscal year 2022: TECH 25.4%
  7. Fiscal year 2023: TECH 19.0%
  8. Fiscal year 2024: TECH 20.4%
  9. Fiscal year 2025: TECH 21.0%
  10. Fiscal year 2026: TECH 21.7% · Sector today 15.8%

Source: SEC filings, fiscal years up to Jun 30, 2026. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 5.2x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
0.0%
dividend per share, average per year
Coverage by free cash flow
5.2x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2021 0.32 USD → fiscal year 2026 0.32 USD = 0.0% per year
  • Free cash flow per share 1.68 USD ÷ dividend per share 0.32 USD = 5.2x

Years without a cut: in a row up to fiscal year 2026, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2026 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is about at its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
0.32 USD · Fiscal year 2026
Dividend growth per year
3 y 0.0%5 y 0.0%10 y 0.0%
Payout ratio
of earnings 28% of free cash flow 19%
To shareholders (5 years)
829.2M USD 70% through repurchases
Share count over 5 years
−3.0% fewer shares – each share is a larger stake

Dividend per share

The dividend per share stayed roughly the same in 5 years (0.32 USD).

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2017: Dividend per share 0.32 USD
  2. Fiscal year 2018: Dividend per share 0.32 USD
  3. Fiscal year 2019: Dividend per share 0.32 USD
  4. Fiscal year 2020: Dividend per share 0.32 USD
  5. Fiscal year 2021: Dividend per share 0.32 USD
  6. Fiscal year 2022: Dividend per share 0.32 USD
  7. Fiscal year 2023: Dividend per share 0.32 USD
  8. Fiscal year 2024: Dividend per share 0.32 USD
  9. Fiscal year 2025: Dividend per share 0.32 USD
  10. Fiscal year 2026: Dividend per share 0.32 USD

Payout ratios

The payout ratio fell in 5 years from 36.9% to 27.6%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2017: Payout ratio (earnings) 63.1% · Payout ratio (free cash flow) 36.8%
  2. Fiscal year 2018: Payout ratio (earnings) 38.7% · Payout ratio (free cash flow) 32.1%
  3. Fiscal year 2019: Payout ratio (earnings) 51.8% · Payout ratio (free cash flow) 31.0%
  4. Fiscal year 2020: Payout ratio (earnings) 22.0% · Payout ratio (free cash flow) 31.9%
  5. Fiscal year 2021: Payout ratio (earnings) 36.9% · Payout ratio (free cash flow) 16.1%
  6. Fiscal year 2022: Payout ratio (earnings) 19.3% · Payout ratio (free cash flow) 17.9%
  7. Fiscal year 2023: Payout ratio (earnings) 18.2% · Payout ratio (free cash flow) 23.3%
  8. Fiscal year 2024: Payout ratio (earnings) 30.5% · Payout ratio (free cash flow) 21.4%
  9. Fiscal year 2025: Payout ratio (earnings) 69.6% · Payout ratio (free cash flow) 19.6%
  10. Fiscal year 2026: Payout ratio (earnings) 27.6% · Payout ratio (free cash flow) 19.0%

What goes back to shareholders

Over 5 years, 829.2M USD went back to shareholders, 70% of it through share repurchases. That is 66% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2017: Dividends paid 47.3M USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 128.5M USD
  2. Fiscal year 2018: Dividends paid 48.0M USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 149.4M USD
  3. Fiscal year 2019: Dividends paid 48.4M USD · Share repurchases 15.4M USD · New shares issued (including employee plans) not available · Free cash flow 156.2M USD
  4. Fiscal year 2020: Dividends paid 48.9M USD · Share repurchases 50.1M USD · New shares issued (including employee plans) not available · Free cash flow 153.5M USD
  5. Fiscal year 2021: Dividends paid 49.6M USD · Share repurchases 43.2M USD · New shares issued (including employee plans) not available · Free cash flow 307.9M USD
  6. Fiscal year 2022: Dividends paid 50.2M USD · Share repurchases 161.0M USD · New shares issued (including employee plans) not available · Free cash flow 280.4M USD
  7. Fiscal year 2023: Dividends paid 50.3M USD · Share repurchases 19.6M USD · New shares issued (including employee plans) not available · Free cash flow 216.1M USD
  8. Fiscal year 2024: Dividends paid 50.4M USD · Share repurchases 80.0M USD · New shares issued (including employee plans) not available · Free cash flow 236.1M USD
  9. Fiscal year 2025: Dividends paid 50.4M USD · Share repurchases 275.7M USD · New shares issued (including employee plans) not available · Free cash flow 256.6M USD
  10. Fiscal year 2026: Dividends paid 49.9M USD · Share repurchases 41.7M USD · New shares issued (including employee plans) not available · Free cash flow 263.2M USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Bio-Techne next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison TECH, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
MRNA Moderna 1.9B USD +19.3%55.3%−158.1%−145.2%−32.6%70.1%−106.2%2/9
TECH Bio-Techne this stock 1.2B USD +5.5%65.8%20.7%15.0%8.6%81.5%21.7%9/9
NVAX Novavax 1.1B USD +18.8%93.5%40.3%39.2%–−10.9%−22.3%5/9
IOVA Iovance Biotherapeutics 263.5M USD –34.3%−153.1%−148.4%−56.0%76.5%−127.6%–
IBRX ImmunityBio 113.3M USD +299.7%–−226.0%−310.2%–−99.7%−272.6%–
Median of the sector 27 symbols 44.3B USD +8.4%67.2%18.2%14.6%13.6%38.5%15.8%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector TECH next to NVAX – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+5.5% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 5.5% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light yellow: below sector

+5.3% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: +6.0% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 5.3% per year on average, but more slowly than the median company in the sector (+5.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

15.0% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 14.97 USD remained as profit – at least as much as the median company in the sector (13.9%). Five years ago the margin was 15.1%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.09 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.09 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

28% Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.28 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 56%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
1.2B USD
Revenue vs. prior year
−0.4%
Net income (FY)
181.9M USD
Net income vs. prior year
+147.8%
EPS (FY)
1.16 USD
Superinvestors holding
3 of 26
Fiscal year to Jun 30, 2026 · 10-K filed Aug 24, 2026 · Balance sheet Jun 30, 2026 (filed Aug 24, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2026Jun 30, 2026 1.2B181.9M 15.0% 1.16 0.32 28%
2025Jun 30, 2025 1.2B73.4M 6.0% 0.46 0.32 70%
2024Jun 30, 2024 1.2B168.1M 14.5% 1.05 0.32 30%
2023Jun 30, 2023 1.1B285.3M 25.1% 1.76 0.32 18%
2022Jun 30, 2022 1.1B272.1M 24.6% 1.66 0.32 19%
2021Jun 30, 2021 931.0M140.4M 15.1% 0.87 0.32 37%
2020Jun 30, 2020 738.7M229.3M 31.0% 1.46 0.32 22%
2019Jun 30, 2019 714.0M96.1M 13.5% 0.62 0.32 52%
2018Jun 30, 2018 643.0M126.2M 19.6% 0.83 0.32 39%
2017Jun 30, 2017 563.0M76.1M 13.5% 0.51 0.32 63%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 299.7M28.3M 9.4% 0.18 0.08 44%
Q2/26*Jun 30, 2026 321.2M– – – – –
Q1/26Mar 31, 2026 311.4M51.0M 16.4% 0.32 0.08 25%
Q4/25Dec 31, 2025 295.9M38.0M 12.8% 0.24 0.08 33%
Q3/25Sep 30, 2025 286.6M38.2M 13.3% 0.24 0.08 33%
Q2/25*Jun 30, 2025 317.0M−17.7M −5.6% – 0.08 –
Q1/25Mar 31, 2025 316.2M22.6M 7.1% 0.14 0.08 57%
Q4/24Dec 31, 2024 297.0M34.9M 11.7% 0.22 0.08 36%
Q3/24Sep 30, 2024 289.5M33.6M 11.6% 0.21 0.08 38%
Q2/24*Jun 30, 2024 –40.6M – – 0.24 –
Q1/24Mar 31, 2024 303.4M49.1M 16.2% 0.31 0.08 26%
Q4/23Dec 31, 2023 272.6M27.5M 10.1% 0.17 0.08 47%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Per-share values adjusted for stock split 4:1 (between Nov 7, 2022 and Feb 7, 2023). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $00 people $0
6 months $00 people $00 people $0
12 months $00 people $437.2K1 person −$437.2K

Latest transactions

  • May 8, 2026 Herr Amy E. Director Open-market sale 6,636 shares · $320.4K · SEC
  • Feb 17, 2026 Herr Amy E. Director Open-market sale 1,976 shares · $116.8K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Bio-Techne?

All superinvestor portfolios

3 of 26 tracked superinvestors report a position.

Superinvestors with a position in Bio-Techne, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Paul Tudor Jones Tudor Investment Corp 0.3% −9.3% reduced Q3 2026
Renaissance Technologies < 0.1% new Q3 2026
Steve Cohen Point72 Asset Management < 0.1% new Q3 2026

Sold out in the latest quarter: Soros Fund Management, Bridgewater Associates.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on TECH yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: TECH

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close